fig2

Figure 2. Key signaling pathways in intrahepatic cholangiocarcinoma. A simplified view of pathways activated by genetic alterations identified in iCCA. Mutations in receptor tyrosine kinases like EGFR, ERBB, MET, and FGFR2 fusions dysregulate signaling of the RAS/MAPK and PI3K/AKT pathways. Uncontrolled TGF-β signaling is defined by loss-of-function mutations in SMAD4 and is linked to dysregulated signaling through the TAK1 pathway. Mutations in IDH1/2 lead to increased levels of 2-HG and increased YAP/TAZ-directed transcription. Created with https://www.biorender.com/.